Riluzole
Basic Information
| Item | Value |
|---|---|
| DrugBank ID | DB00740 |
| Evidence Level | L5 (Computational Prediction) |
| Number of Predicted Indications | 86 |
Predicted Indications (TxGNN)
The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.
| # | Indication | Source |
|---|---|---|
| 1 | bilateral parasagittal parieto-occipital polymicrogyria | KG + DL |
| 2 | axial spondylometaphyseal dysplasia | KG + DL |
| 3 | lower motor neuron syndrome with late-adult onset | KG + DL |
| 4 | trichomegaly-retina pigmentary degeneration-dwarfism syndrome | KG + DL |
| 5 | lethal arthrogryposis-anterior horn cell disease syndrome | KG + DL |
| 6 | monomelic amyotrophy | KG + DL |
| 7 | Mills syndrome | KG + DL |
| 8 | amyotrophic lateral sclerosis, susceptibility to | KG + DL |
| 9 | autosomal dominant mitochondrial myopathy with exercise intolerance | KG + DL |
| 10 | amyotrohpic lateral sclerosis type 22 | KG + DL |
| 11 | polymicrogyria, perisylvian, with cerebellar hypoplasia and arthrogryposis | KG + DL |
| 12 | hydranencephaly (disease) | KG + DL |
| 13 | congenital disorder of glycosylation with defective fucosylation | KG + DL |
| 14 | schizophrenia | KG + DL |
| 15 | retinal dystrophy with or without extraocular anomalies | KG + DL |
| 16 | atypical glycine encephalopathy | KG + DL |
| 17 | Charcot-Marie-Tooth disease, demyelinating, type 1G | KG + DL |
| 18 | myopia 26, X-linked, female-limited | KG + DL |
| 19 | syndromic myopia | KG + DL |
| 20 | myopia X-linked | KG + DL |
| 21 | proximal spinal muscular atrophy | KG + DL |
| 22 | acute intermittent porphyria | KG + DL |
| 23 | PLA2G6-associated neurodegeneration | KG + DL |
| 24 | renal pelvis carcinoma | KG + DL |
| 25 | paralysis agitans, juvenile, of Hunt | KG + DL |
| 26 | short rib-polydactyly syndrome, Majewski type | KG + DL |
| 27 | renal cell carcinoma (disease) | KG + DL |
| 28 | lethal infantile mitochondrial myopathy | KG + DL |
| 29 | febrile infection-related epilepsy syndrome | KG + DL |
| 30 | Lennox-Gastaut syndrome | KG + DL |
| 31 | dermatofibrosarcoma protuberans | KG + DL |
| 32 | Parkinson disease | KG + DL |
| 33 | hereditary coproporphyria | KG + DL |
| 34 | perioral myoclonia with absences | KG + DL |
| 35 | rhabdoid tumor | KG + DL |
| 36 | atypical childhood epilepsy with centrotemporal spikes | KG + DL |
| 37 | cryptogenic late-onset epileptic spasms | KG + DL |
| 38 | photosensitive occipital lobe epilepsy | KG + DL |
| 39 | adolescent/adult-onset epilepsy syndrome | KG + DL |
| 40 | neuronopathy, distal hereditary motor | KG + DL |
| 41 | distal 17p13.3 microdeletion syndrome | KG + DL |
| 42 | familial encephalopathy with neuroserpin inclusion bodies | KG + DL |
| 43 | infantile neuronal ceroid lipofuscinosis | KG + DL |
| 44 | frontotemporal neurodegeneration with movement disorder | KG + DL |
| 45 | poliomyelitis | KG + DL |
| 46 | adolescence-adult electroclinical syndrome | KG + DL |
| 47 | gastrocutaneous syndrome | KG + DL |
| 48 | myoclonic epilepsy, juvenile, susceptibility to | KG + DL |
| 49 | familial generalized lentiginosis | KG + DL |
| 50 | acromelanosis | KG + DL |
(Showing top 50 of 86 predictions)
Disclaimer
These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.